Please use this identifier to cite or link to this item:
|Title:||Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin|
|Authors:||Lim, Soo;Stember, Katherine G.;He, Wei;Bianca, Porneala C.;Yelibi, Carine;Marquis, Alison;Stürmer, Til;Buse, John B.;Meigs, James B.|
|subject:||Biology and Life Sciences;Biochemistry;Hormones;Insulin;Medicine and Health Sciences;Clinical Medicine;Endocrinology;Diabetic Endocrinology;Epidemiology;Epidemiological Methods and Statistics;Health Care;Health Care Policy;Health Risk Analysis;Oncology;Cancer Risk Factors;Pharmacology;Drug Research and Development;Clinical Research Design;Longitudinal Studies|
|Publisher:||Public Library of Science|
|Description:||Background: Recent studies suggested that insulin glargine use could be associated with increased risk of cancer. We compared the incidence of cancer in new users of glargine versus new users of NPH in a longitudinal clinical cohort with diabetes for up to 6 years. Methods and Findings: From all patients who had been regularly followed at Massachusetts General Hospital from 1/01/2005 to 12/31/2010, 3,680 patients who had a medication record for glargine or NPH usage were obtained from the electronic medical record (EMR). From those we selected 539 new glargine users (age: 60.1±13.6 years, BMI: 32.7±7.5 kg/m2) and 343 new NPH users (61.5±14.1 years, 32.7±8.3 kg/m2) who had no prevalent cancer during 19 months prior to glargine or NPH initiation. All incident cancer cases were ascertained from the EMR requiring at least 2 ICD-9 codes within a 2 month period. Insulin exposure time and cumulative dose were validated. The statistical analysis compared the rates of cancer in new glargine vs. new NPH users while on treatment, adjusted for the propensity to receive one or the other insulin. There were 26 and 28 new cancer cases in new glargine and new NPH users for 1559 and 1126 person-years follow-up, respectively. There were no differences in the propensity-adjusted clinical characteristics between groups. The adjusted hazard ratio for the cancer incidence comparing glargine vs. NPH use was 0.65 (95% CI: 0.36–1.19). Conclusions: Insulin glargine is not associated with development of cancers when compared with NPH in this longitudinal and carefully retrieved EMR data.|
|Standard no:||Lim, Soo, Katherine G. Stember, Wei He, Porneala C. Bianca, Carine Yelibi, Alison Marquis, Til Stürmer, John B. Buse, and James B. Meigs. 2014. “Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin.” PLoS ONE 9 (10): e109433. doi:10.1371/journal.pone.0109433. http://dx.doi.org/10.1371/journal.pone.0109433.|
|Appears in Collections:||HMS Scholarly Articles|
Files in This Item:
Click on the URI links for accessing contents.
Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.